Bergamot Extract.

Bergamot's HMG-flavanones (brutieridin and melitidin) act on the same cholesterol-synthesis step in the liver that monacolin K from red yeast rice occupies, which is why the two are routinely built into one lipid-support formula. Pairing them lets a formulator spread that support across two sources rather than raising the monacolin load.

Berberine works on the clearance side, stabilising LDL-receptor mRNA and lowering PCSK9 so the liver pulls more LDL particles out of circulation. Bergamot polyphenols act on the production side of hepatic cholesterol synthesis, so the two engage different points of the same pathway and are commonly combined for that reason.

EPA and DHA reduce hepatic VLDL assembly and raise triglyceride clearance, a separate lipid fraction from the cholesterol-synthesis route bergamot influences. Formulas pair them so one product covers both sides of a normal lipid panel.

Artichoke caffeoylquinic acids raise bile flow, which increases cholesterol loss through the biliary route. Bergamot flavonoids act on synthesis inside the cell, so output and production are addressed separately.

CoQ10 is built on the same mevalonate branch that sits downstream of HMG-CoA reductase, the step bergamot flavonoids damp. Supplying it alongside covers the branch that quietens with the shared upstream step.

Plant sterols displace cholesterol from intestinal micelles so less crosses the gut wall. Bergamot acts on internal synthesis, which makes the two arms complementary rather than redundant.

Psyllium binds bile acids and removes them in stool, so the liver draws more circulating cholesterol to rebuild the pool. That lever is independent of the flavonoid effect on synthesis.

Tocotrienols push degradation of the HMG-CoA reductase protein itself while flavonoids act on its activity. Two mechanisms on one enzyme step is well described in mevalonate pathway pharmacology.

Beta-glucan thickens gut contents and interrupts bile acid recycling, raising hepatic cholesterol turnover. The mechanism sits in the gut lumen and does not overlap with intracellular synthesis.

Niacin damps adipose fatty acid release and hepatic VLDL assembly through receptor signalling. That is a different point of control from flavonoid action on cholesterol synthesis.

Piperine inhibits glucuronidation, the main route by which flavonoids are conjugated and cleared. Less conjugation keeps more of the active bergamot polyphenol in circulation.

Monacolin K inhibits HMG-CoA reductase directly and is cleared by CYP3A4, which bergamot furanocoumarins slow. Action on the enzyme becomes additive while monacolin exposure rises, so the pair calls for careful dosing rather than casual stacking.

Hesperidin is one of the flavanone glycosides that occurs naturally in Citrus bergamia juice and is a marker compound in standardised bergamot fractions. Adding isolated hesperidin to a bergamot product increases the same class of molecule the extract already supplies. Read it as a dose question rather than a new mechanism.

Naringin and its aglycone naringenin are among the flavanones bergamot extracts are standardised on, alongside neoeriocitrin and the statin-like brutieridin and melitidin. Supplying naringin separately overlaps with what the extract contributes. The pairing is compositional rather than complementary.

Ascorbate regenerates oxidised flavonoid radicals back to their reduced form in the classic antioxidant network, and citrus fruit supplies both together. The interaction is a settled redox relationship measured in chemical and cell systems. It is not a claim about a clinical endpoint.

Quercetin and the bergamot flavanones sit in the same polyphenol class and compete for the same phase two conjugation enzymes, UGT and SULT, in the gut wall and liver. Taken together they can slow each other's clearance while adding to the same antioxidant pool. Both parts of that are mechanistic observations.

Grape seed proanthocyanidins are routinely stacked with citrus flavonoids in vascular and lipid-support formulas because the two polyphenol classes have different absorption profiles. The overlap is in the endpoint targeted rather than in the molecule. Combination-specific human data is limited.

Pine bark procyanidins and bergamot flavanones appear together in circulation-support products, each with its own single-ingredient literature. Their effects on oxidative and endothelial markers are expected to add. Markers, not outcomes, are what those studies measure.

Catechins and citrus flavanones both engage intestinal efflux transporters and the same conjugation enzymes, so co-dosing changes how much of each survives first pass. The direction is generally toward higher exposure of the more heavily metabolised partner. This is a pharmacokinetic interaction to be aware of when stacking polyphenols.

Resveratrol and bergamot polyphenols are combined in formulas built around lipid handling and oxidative markers, and both undergo extensive glucuronidation that limits free plasma concentrations. Sharing that conjugation route means each can slow the other's clearance. The additive framing applies to markers rather than to any clinical endpoint.

The dihydrolipoate and lipoate couple regenerates other antioxidants including ascorbate and, indirectly, oxidised polyphenol species. Placing it alongside a flavonoid-rich extract puts two members of the same redox network in one formula. The relationship is established redox chemistry.

Aged garlic and bergamot appear together in products aimed at supporting normal lipid and vascular function, each with independent human data at that endpoint. Their mechanisms differ, which is the stated rationale for combining them. The combination itself has been studied much less than either component.

Silymarin flavonolignans inhibit UGT and several CYP isoforms, the same routes that conjugate citrus flavanones on first pass. Co-dosing can raise circulating polyphenol concentrations relative to either taken alone. Anyone on medication cleared by those enzymes should have the stack reviewed by their clinician.

Most flavanone glycosides are not absorbed intact; colonic bacteria cleave the sugar and produce the smaller phenolic acids that actually appear in plasma. A prebiotic that shifts that community can shift which metabolites are formed. The dependency on microbial conversion is established, the effect of adding a specific prebiotic is not.

Bacterial beta-glucosidase and rhamnosidase activity releases the flavanone aglycones from their glycosides, which is the step that makes them absorbable. Different bacterial populations carry that activity to different degrees. In vitro work with human faecal bacteria is where most of this evidence sits, so it grounds a mechanism rather than an outcome.

Viscous fibre and bergamot extract are combined in lipid-support formulas because the fibre acts in the gut lumen on bile acid and sterol handling while the polyphenols act after absorption. The rationale is complementary sites of action. A viscous gel can also slow the absorption of small molecules taken with it, so timing matters.

Astragalus, pineapple stem and bergamot extracts were assessed together against human faecal bacteria in a single in vitro fermentation model, where each altered the microbial profile. That is a bench observation in a culture system, not a human result. It grounds a plausible interaction at the level of the gut community only.